• Erastin in Ferroptosis Research: Evidence and Limits

  2026-10-06

  Erastin is a research tool for studying ferroptosis, redox vulnerability and genotype-associated cancer biology. This overview distinguishes supplier-described mechanisms from peer-reviewed evidence, examines findings from a pancreatic adenocarcinoma lncRNA study, and explains the limits of translating computational associations into treatment claims.

• Bazedoxifene in Osteoporosis: Evidence from a 2019 Review

  2026-10-06

  The 2019 review by Yavropoulou, Makras, and Anastasilakis synthesizes randomized phase III evidence on Bazedoxifene, emphasizing its long-term clinical profile, vertebral fracture efficacy, and tissue-selective pharmacology. Its main practical implication is a carefully bounded one: Bazedoxifene may support long-term management of postmenopausal osteoporosis, but its benefits are strongest for vertebral outcomes and do not clearly exceed those of established antiresorptive therapies.

• Beyond Expression: Translating OX40L mRNA

  2026-10-05

  A source-grounded perspective on how mouse OX40L mRNA can support mechanistic co-stimulation research while keeping expression evidence, functional interpretation, and translational claims distinct.

• Protoporphyrin IX: Heme, Light, and Iron

  2026-10-05

  Protoporphyrin IX sits at the intersection of heme formation, photodynamic biology, and iron-dependent cell death. This article clarifies what the HCC ferroptosis literature does—and does not—show about interpreting this photodynamic compound in cancer research.

• GW4064: Reading FXR Signals Beyond Metabolism

  2026-10-04

  GW4064 is a non-steroidal FXR agonist that connects bile acid, lipid, inflammatory, and ferroptosis research. This article explains how the compound should be interpreted as a context-sensitive mechanistic probe, using a 2025 LX-2 cell study to separate receptor activation from downstream fibrosis outcomes.

• c-Myc Tag Peptide: Evidence and Assay Meaning

  2026-10-03

  The c-Myc Peptide is best understood as an epitope-competition reagent rather than a model of full-length c-Myc biology. This article distinguishes binding evidence from transcription-factor interpretation and places the product in context with research on regulated IRF3 stability.

• SETD7 Depletion Promotes White Adipose Browning

  2026-10-02

  The reference study identifies SETD7 as a negative regulator of inguinal white adipose tissue thermogenesis and links its depletion to an Adcy7–Sirt1–CREB1 signaling route. In obese mice, reducing SETD7 enhanced beige-fat activity, increased energy expenditure, and improved metabolic phenotypes without substantially changing brown adipose thermogenesis.

• NADH Workflows for Redox and Mitochondrial Research

  2026-10-01

  Build practical NADH assays around mitochondrial respiration, redox perturbation, and translational disease models. This guide connects fresh-solution handling and controls with the Catalpol–SIRT1/HIF-1α workflow, while distinguishing validated findings from starting-point optimization in photocatalytic cancer therapy.

• Protoporphyrin IX in Ferroptosis and Photodynamic Assays

  2026-10-01

  Use Protoporphyrin IX as an iron-handling probe, fluorescence-active photodynamic compound, or orthogonal control in cancer and heme-biology workflows. This guide connects practical formulation and light-exposure decisions with the METTL16–SENP3–LTF ferroptosis mechanism reported in hepatocellular carcinoma.

• RHEB Neddylation Drives mTORC1 in Liver Cancer

  2026-09-30

  The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation machinery and maps a functional modification to lysine 169. By combining cellular, biochemical, liver-specific genetic, and clinical association analyses, it links RHEB neddylation to mTORC1 activation, steatosis, liver tumorigenesis, and hepatocellular carcinoma outcomes.

• c-Myc Tag Peptide: Assay Control to Translation

  2026-09-30

  A translational perspective on how the c-Myc tag Peptide improves epitope-specific assay control, clarifies protein-regulation mechanisms, and supports more rigorous interpretation of cancer and innate-immunity studies.

• ALC-0159 PEG Lipid for mRNA LNP Workflows

  2026-09-29

  Use ALC-0159 as a controlled PEG-lipid variable when optimizing mRNA lipid nanoparticles for expression, stability, and immune-readout studies. This workflow connects formulation development with cancer-immunotherapy assays while clearly separating product-specific evidence from findings reported for complete vaccine systems.

• JNJ-26481585: Workflow for Resistance Research

  2026-09-29

  JNJ-26481585 (Quisinostat) combines potent HDAC inhibition with a practical workflow for studying TRIM21–ERK1/2 signaling, apoptosis, and treatment resistance. This guide translates the pituitary adenoma findings into reproducible cell-based assays, mechanism controls, and tumor-model validation strategies.

• TRIM66 and Monogenic Olfactory Receptor Choice

  2026-09-28

  The reference study identifies TRIM66 as an epigenetic repressor that helps convert initially polygenic olfactory receptor expression into the mature one-neuron–one-receptor state. Genetic, molecular, and behavioral evidence links TRIM66-dependent enhancer repression to olfactory sensory neuron identity, neural activity, and innate olfactory behavior.

• Temafloxacin Activity Against Gram-Positive Bacteria

  2026-09-28

  This 1991 study paired broth microdilution testing of bloodstream isolates with a review of published evidence to assess temafloxacin against clinically important Gram-positive cocci. It reported greater in-vitro activity than ciprofloxacin or ofloxacin against the tested staphylococci and pneumococci, while showing that assay conditions such as urine composition and magnesium concentration can influence interpretation.

8092 records 1/540 page Next 12345 下5页 Last page